Binghamton researchers get FDA approval for drug to treat world’s most common genetic disease

Eric Hoffman, professor of pharmaceutical sciences and associate dean of research and research development, and Kanneboyina Nagaraju, professor of pharmaceutical sciences and dean of the School of Pharmacy and Pharmaceutical Sciences, have spent 13 years developing vamorolone. More: https://www.binghamton.edu/news/story/4564/binghamton-researchers-get-fda-approval-for-drug-to-treat-worlds-most-common-genetic-disease